Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug;82(8):1117-1120.
doi: 10.1136/ard-2023-223952. Epub 2023 May 5.

Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells

Christina Bergmann  1   2 , Fabian Müller  2   3 , Jörg H W Distler  1   2   4   5 , Andrea-Hermina Györfi  4   5 , Simon Völkl  2   3 , Michael Aigner  2   3 , Sascha Kretschmann  2   3 , Hannah Reimann  2   3 , Thomas Harrer  1   2 , Nadine Bayerl  6 , Sebastian Boeltz  1   2 , Andreas Wirsching  1   2 , Jule Taubmann  1   2 , Wolf Rösler  2   3 , Bernd Spriewald  2   3 , Jochen Wacker  1   2 , Armin Atzinger  7 , Michael Uder  6 , Torsten Kuwert  7 , Andreas Mackensen  2   3 , Georg Schett  8   2
Affiliations

Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells

Christina Bergmann et al. Ann Rheum Dis. 2023 Aug.
No abstract available

Keywords: B-Lymphocytes; Systemic Sclerosis; Treatment.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Patient with severe diffuse systemic sclerosis treated with CD19-CAR T cells. (A) Dot plot showing expression of CD3 (y-axis) and CD19-CAR (x-axis) quantifying the circulating CD19-CAR T cells by FACS on days 3 and 9 after infusion. (B) Time course of absolute and relative numbers of circulating CD19-CAR T cells and CD19+ B cells; d0=01.080.2022. (C) Densitometric analysis of autoantibodies against RNAPIII, subunit RP11 at baseline (1 month prior to CAR T-cell infusion) and 3 months after CAR T-cell therapy. (D) PET showing resolution of fibroblast activation protein inhibitor (68Ga-FAPI-04) tracer accumulation in the heart at baseline and 3 months after CAR T-cell therapy. (E) Axial and coronal sections of T1-weighted contrast-enhanced MRI of the hands at baseline and 3 months after CAR T-cell therapy. (F) EUSTAR activity index, (G) mRSS and (H) lung function parameters at baseline and 3 months after CAR T-cell therapy. mRSS changes (G) were visualised using a modified version of the scheme described in Khanna D, Furst de, et al. J scleroderma relat Disord.2017 Jan-Apr;2 (1):11–18.doi:10.5301/jsrd.5000231. CAR, chimeric antigen receptor; CRP, C reactive protein; DLCO, diffusing capacity or transfer factor of the lung for carbon monoxide; EF, ejection fraction; FACS, fluorescence-activated cell scanner; KCO, carbon monoxide transfer coefficient; mRSS, modified Rodnan Skin Score; PASP, pulmonary artery systolic pressure; PET, positron emission tomography; PFT, pulmonary function tests; RA, right atrium; SUV, standard uptake value; TFR, tendon friction rubs; TTE, transthoracic echocardiography.
See this image and copyright information in PMC

References

    1. Sato S, Fujimoto M, Hasegawa M, et al. . Altered blood B lymphocyte homeostasis in systemic sclerosis: Expanded naive B cells and diminished but activated memory B cells. Arthritis Rheumatol 2004;50:1918–27. 10.1002/art.20274 - DOI - PubMed
    1. Ebata S, Yoshizaki A, Oba K, et al. . Safety and efficacy of Rituximab in systemic sclerosis (DESIRES): A double-blind, investigator-initiated, randomised, placebo-controlled trial. The Lancet rheumatology 2021;3:e489–97. 10.1016/S2665-9913(21)00107-7 - DOI - PubMed
    1. Maher TM, Tudor VA, Saunders P, et al. . Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): A double-blind, double-dummy, randomised, controlled, phase 2B trial. Lancet (London, England) 2023;11:45–54. 10.1016/S2213-2600(22)00359-9 - DOI - PubMed
    1. van Laar JM, Farge D, Sont JK, et al. . Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: A randomized clinical trial. Jama 2014;311:2490. 10.1001/jama.2014.6368 - DOI - PubMed
    1. Mougiakakos D, Krönke G, Völkl S, et al. . Cd19-targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med 2021;385:567–9. 10.1056/NEJMc2107725 - DOI - PubMed

Publication types

Substances